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Abstract
Objective: We aimed to investigate whether elevated serum uric acid concentrations are associated with higher
risk of metabolic syndrome (MetS) and carotid atherosclerosis in patients with type 2 diabetes.
Methods: We conducted a population-based cross-sectional survey in Shanghai, with a total of 395 men and 631
women age 41 to 92 years. The carotid artery intima-media thickness (IMT) and carotid atherosclerotic plaques
(PLQ) were measured by B-mode ultrasound. MetS was defined according to the updated National Cholesterol
Education Program Adult Treatment Panel III criteria for Asian Americans.
Results: Uric acid levels were negatively associated with duration of diabetes, fasting plasma glucose,
glycohemoglobin, eGFR, HDL-cholesterol (all P < 0.001) and positively with BMI, CRP, waist circumference,
triglycerides, systolic blood pressure, ACR, HOMA-IR and IMT (all P < 0.05). In the highest quartile of uric acid levels,
the risks were substantially higher for MetS [odds ratio 3.97, (95% confidence interval 2.58-6.13)] (P < 0.001 for
trend) and PLQ [odds ratio 2.71 (95% confidence interval 1.62-4.47)] (p = 0.013 for trend) compared with that in
the lowest quartile of uric acid levels after multiple adjustment. These associations remained significant after further
adjustment for potential confounders.
Conclusions: Serum uric acid level is associated with MetS and is an independent risk factor for carotid
atherosclerosis in patients with type 2 diabetes.
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Introduction
Metabolic syndrome (MetS), a clustering of cardiovascu-
lar risk factors such as insulin resistance, hypertension,
glucose intolerance, hypertriglyceridemia, and low high-
density lipoprotein (HDL) cholesterol levels, is a major
worldwide public health problem[1]. The prevalence of
MetS is increasing in China because of the westerniza-
tion of the lifestyle, such as a high-fat and high-calorie
diet and less physical activity. A recent epidemiological
s t u d yi n d i c a t e dt h a tt h ep r e v a l e n c eo fM e t Sa m o n g
Chinese men and women aged 35 to 64 years was 9.8%
and 17.8%, respectively[2].
Uric acid is the end product of purine metabolism in
humans. Excess serum accumulation can lead to various
diseases, and most notably uric acid is causally involved
in the pathogenesis of gouty arthritis [3-5]. Recent stu-
dies have suggested that hyperuricemia is a risk factor
for cardiovascular disease (CVD) in the general popula-
tion [6-8]. However, despite the clinical and epidemiolo-
gical evidence, some authorities have considered that
the association was confounded by other well-estab-
lished risk factors for CVD [3,9].
Recently, growing evidence demonstrates that uric
acid may have a key role in the pathogenesis of MetS
[10]. Recent studies in animals models report that uric
acid may play a causal role in the development of MetS
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features of the MetS [11].
Although previous studies have analyzed the indepen-
dence of the relationship between uric acid and MetS
and carotid atherosclerosis, thus far, few have examined
in type 2 diabetes and there is a scarcity of data evaluat-
ing the effect of MetS on the association between serum
uric acid and carotid atherosclerosis. In this study, we
aimed to investigate the association between the serum
uric acid and MetS and carotid atherosclerosis in
patients with type 2 diabetes.
Methods
Study subjects
A cross-sectional study to evaluate the prevalence of
diabetic complications in Chinese patients aged over
30 and diagnosed with type 2 diabetes was planned in
downtown Shanghai. The details of the study design
have been described previously[12]. In brief, the study
was conducted from February to July 2004. 20 residen-
tial areas administered by 20 residents’ committees
were sampled randomly in the central area of Shang-
hai. Questionnaires to identify diabetes history were
sent to every household in the 20 residential areas and
collected by primary care clinicians and endocrinolo-
gists. A total of 1120 Chinese patients diagnosed with
type 2 diabetes were identified via the questionnaire.
Finally, 1039 Chinese patients diagnosed with type 2
diabetes were enrolled in our study. After excluding
those who did not have serum uric acid data (n = 13),
1026 individuals (395 men and 631 women) were eligi-
ble for the present analysis. The study was approved
by the Institution Review Board of the Huashan Hospi-
tal, and written informed consents were obtained from
all participants.
Laboratory measurements
Overnight fasting blood samples were collected in tubes
containing liquid EDTA, centrifuged at 4°C, and stored
at -80°C until analysis. The measurements of total cho-
lesterol, HDL-cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides, glucose, insulin, creatinine, and
C-reactive protein (CRP) were previously described
[12,13]. Insulin resistance was estimated using homeos-
tasis model assessment index-insulin resistance
(HOMA-IR) [14]. A sterile, random-spot urine sample
was used to measure the albumin/creatinine ratio
(ACR). We used the modification of diet in renal disease
(MDRD) equation re-calibrated for Chinese to estimate
eGFR expressed in ml/min/1.73 m
2: eGFR = 186 × [SCR
× 0.011]
-1.154 ×[ a g e ]
-0.203 × [0.742 if female] × 1.233,
where SCR is serum creatinine expressed as μmol/l and
1.233 is the coefficient for Chinese.
Carotid ultrasonography
Carotid ultrasonography was performed using an Acu-
son Sequoia 512. Trained and certified sonographers
conducted the examination. The ultrasound scanning
protocol in our study was modified in terms of proce-
dures used in previous studies [15-17]. Computer-
assisted edge-detection software was not used for mea-
surement of carotid intima-media thickness (IMT). A
lateral view of bilateral images of common carotid
arteries (1 cm proximal to the dilatation of the carotid
bulb), carotid bulb (identified by the loss of the parallel
wall present in the common carotid artery) and internal
carotid artery (1 cm distal to the tip of the flow divider
that separates the external and internal carotid arteries)
was obtained. Sonographers recorded the images and
completed ultrasound readings. IMT is the distance
between the lumen-intima interface and the media-
adventitia interface [18]. Common carotid artery IMT
was defined as the mean of the maximum IMT in both
right and left sides of common carotid artery.
The plaque of carotid artery (common carotid artery,
carotid bulb and internal carotid artery) is defined as a
localized protrusion of the internal part of the vessel
wall into the lumen of 50% of the surrounding IMT
value. Plaque presence was defined as ≥1p l a q u ei na n y
of the carotid arteries [19].
Definition of MetS
The MetS was defined based on the updated National
Cholesterol Education Program Adult Treatment Panel
III criteria for Asian-Americans[20]: (1) as presenting at
least three of the following components: 1) waist cir-
cumferences 90 cm or greater in men or 80 cm or
greater in women; 2) triglycerides 1.7 mmol/liter or
greater; 3) HDL cholesterol less than 1.03 mmol/liter in
men or less than 1.30 mmol/liter in women; 4) blood
pressure 130/85 mm Hg or greater or current use of
antihypertensive medications; or 5) fasting plasma glu-
cose (FPG) 5.6 mmol/liter or greater or previously diag-
nosed type 2 diabetes or on oral antidiabetic agents or
insulin.
Statistical analysis
Normally distributed data were expressed as means ±
SD, whereas variables with a skewed distribution were
reported as median (interquartile range) and log trans-
formed to approximate normality before analysis. Cate-
gorical variables were represented by frequency and
percentage. Analysis of covariance for continuous vari-
ables and multivariate logistic regression analysis for
categorical variables were applied for the comparison
according to uric acid quartiles. Analysis of covariance
was used to compare uric acid levels between genders.
Li et al. Cardiovascular Diabetology 2011, 10:72
http://www.cardiab.com/content/10/1/72
Page 2 of 7Correlation coefficients between uric acid and metabolic
features were calculated by partial correlation analysis
on ranks (Spearman correlation). Serum uric acid levels
were depicted according to the number of MetS compo-
nents using linear regression model. Multivariate logistic
regression models were used to estimate the odds ratios
(ORs) for MetS. Potential confounding variables includ-
ing age, gender, smoking, alcohol drinking, self-reported
CVD, family history of diabetes, eGFR, HbA1C,C R P ,
HOMA-IR and body mass index (BMI) were controlled
in the regression models. Data management and statisti-
cal analysis were performed using SPSS version 13.0 for
Windows (SPSS, Chicago, IL, USA). P < 0.05 was con-
sidered statistically significant.
Results
Characteristics of participants according to serum uric
acid quartiles
We identified 1026 patients with type 2 diabetes with a
mean age of 65.57 ± 11.70 years. At the time of uric
acid determination, history of hypertension was docu-
mented in 761 patients (74.2%) and CVD in 200 patients
(19.5%). Baseline demographic and medical characteris-
tics for both genders combined and divided by uric acid
quartiles are illustrated in Table 1. When analyzed by
quartiles of uric acid levels, the patients with higher uric
acid were more likely to be male and smokers (both P <
0.05). With respect to metabolic parameters, the patients
in the higher uric acid quartiles exhibited higher levels
of systolic blood pressure, BMI, waist circumference,
HOMA-IR, CRP, IMT, creatinine, ACR and triglycerides
(all P < 0.05). In contrast, the patients with higher uric
acid levels displayed shorter duration of diabetes and
lower levels of FPG, HbA1C, eGFR and HDL cholesterol
(all P < 0.001).
Association between serum uric acid and MetS
Partial correlation analysis demonstrated strong correla-
tion between uric acid and BMI, waist circumference,
HOMA-IR, CRP, TG and HDL cholesterol among var-
ious metabolic features (Table 2).
Remarkably, serum uric acid levels increased gradually
with increasing number of MetS components (Figure 1).
The mean values (SE) of uric acid concentrations signifi-
cantly increased for those with one to five components
were 246.67 (7.89), 268.31 (4.37), 277.91 (4.28), 303.35
(4.56), and 330.35 (6.70) μmol/L, respectively, after
adjustment for age, gender, creatinine, alcohol drinking,
smoking, duration of diabetes, self-reported CVD and
family history of diabetes.
As presented in Table 3, the ORs for MetS were
higher with increasing uric acid quartiles (P < 0.001 for
trend). In the highest uric acid quartile, the ORs were
3.97 [95% confidence interval (CI) 2.58-6.13] for MetS
after adjusting for age, gender, creatinine, alcohol drink-
ing, smoking, duration of diabetes and family history of
diabetes.
Association between serum uric acid and carotid
atherosclerosis
Partial correlation analysis demonstrated a significant cor-
relation between uric acid and IMT (p = 0.02) (Table 2).
As presented in Table 3, the ORs for carotid athero-
sclerotic plaques (PLQ) were higher with increasing uric
acid quartiles (p = 0.013 for trend). In the highest uric
acid quartile, the ORs were 2.71 [95% confidence inter-
val (CI) 1.62-4.47] for PLQ after adjusting for age, gen-
der, eGFR, alcohol drinking, smoking, duration of
diabetes and family history of diabetes.
Effect of MetS on the association between serum uric
acid and PLQ
After adjusting for age, gender, eGFR, alcohol drinking,
smoking, duration of diabetes and family history of dia-
betes, MetS was associated with the PLQ with an odds
ratio of 2.24 (95% CI 1.34-3.57, P < 0.001). Thus, we
next investigated the association between serum uric
acid and PLQ according to the status of MetS. After
adjusting for age, gender, HbA1C,B M I ,s y s t o l i cb l o o d
pressure, diastolic blood pressure, FPG, alcohol drinking,
smoking, duration of diabetes and family history of dia-
betes, in the highest uric acid quartile, the ORs were
1.85 (95% CI 1.14-2.83, p = 0.023) for carotid plaque in
subjects without MetS and 3.07 (95% CI 1.25-6.42) in
subjects with MetS.
Serum uric acid level and glucose control
Hyperglycaemia as reflected by mean HbA1C levels was
associated with lower serum uric acid levels. As sum-
marized in Table 1, the patients with higher uric acid
levels displayed lower HbA1C and fasting glucose levels
(both P < 0.001). HbA1C and FPG were negatively corre-
lated with serum uric acid (Table 2). Moreover, we also
observed that serum uric acid levels were negatively
related to the duration of diabetes (P < 0.001).
Discussion
In the present study, we found that serum uric acid
levels showed association with the risk of MetS and car-
otid atherosclerosis from the cross-sectional data in type
2 diabetes. Moreover, these associations are independent
of lifestyle factors, eGFR, duration of diabetes, family
history of diabetes and remarkably, CRP, HbA1C,
HOMA-IR and BMI.
Possible associations between uric acid and MetS were
evaluated in some studies [10,21]. We also observed that
the ORs were substantially higher for MetS [OR 3.97,
(95% confidence interval 2.58-6.13)] (P < 0.001 for
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4.47)] (p = 0.013 for trend) in the highest serum uric
acid quartile compared with those in the lowest quartile.
In addition, we observed the serum uric acid concentra-
tion increased monotomically with the number of MetS
components (P < 0.001 for trend). However, the under-
lying mechanisms of these associations are still largely
unknown although much research has been done in this
area. Recent studies indicate that hyperuricemia may be
partially responsible for the proinflammatory endocrine
imbalance in the vascular smooth muscle cells and adi-
pose tissue, which is an underlying mechanism of the
low-grade inflammation and insulin resistance in sub-
jects with the CVD and MetS [22,23]. Lowering uric
acid in mice by allopurinol could improve the proin-
flammatory endocrine imbalance in the adipose tissue
by reducing production of monocyte chemoattractant
protein-1 (MCP-1) and increasing production of adipo-
nectin. In addition, lowering uric acid in obese mice
decreased macrophage infiltration in the adipose tissue
and reduced insulin resistance [21]. Moreover, uric acid
has also been shown to induce production of interleukin
1b, interleukin 6, tumor necrosis factor a in human
mononuclear cells, and CRP in cultured human vascular
cells[24], all these have been suggested that uric acid
may have some interaction with other inflammatory
cytokines. In line with views, we observed significant
correlation between serum uric acid and CRP levels
even after adjustment for other potential confounders (r
= 0.08, p = 0.01). Furthermore, we also observed that
CRP increased with serum uric acid quartiles in this
study (P < 0.001), which indicate that uric acid is
Table 1 Characteristics of study participants according to uric acid quartiles
a
Characteristics Q1
(n = 256)
<230
Q2
(n = 257)
231-280
Q3
(n = 256)
281-330
Q4
(n = 257)
≥331
P value
MetS (%) 20.3 35.8 54.3 84.8 <0.001
Uric acid (μmol/L) 200 (190-220) 260 (250-270) 310 (300-320) 390 (350-430) <0.001
Age (yr)
b 65.28 ± 11.27 66.57 ± 10.28 65.09 ± 12.35 67.52 ± 11.84 0.065
Male
b 73 (28.29) 91 (30.33) 92 (41.81) 139 (56.05) <0.001
Smoking (yes) 47 (18.22) 47 (15.67) 52 (23.64) 63 (25.40) 0.017
Alcohol (yes) 27 (10.47) 27 (9.00) 31 (15.50) 38 (15.32) 0.084
Duration of diabetes (yr) 9.72 ± 7.84 7.74 ± 7.04 7.24 ± 6.69 6.75 ± 6.56 <0.001
Self-reported CVD
c 49 (18.99) 62 (20.67) 49 (22.27) 59 (23.79) 0.587
Family history of diabetes
d 112 (43.41) 119 (39.67) 74 (33.64) 84 (33.87) 0.068
SBP (mmHg) 138.44 ± 20.68 139.92 ± 19.82 140.86 ± 22.00 142.31 ± 20.05 <0.001
DBP (mmHg) 80.71 ± 10.54 82.57 ± 10.92 82.14 ± 12.18 82.38 ± 10.69 0.207
BMI (kg/m
2) 24.21 ± 3.39 24.91 ± 3.23 25.40 ± 3.47 25.97 ± 3.39 <0.001
Waist circumference (cm) 81.74 ± 9.68 83.62 ± 8.50 86.05 ± 9.32 87.67 ± 8.88 <0.001
Waist to hip ratio 0.86 ± 0.08 0.87 ± 0.06 0.88 ± 0.06 0.89 ± 0.06 0.176
Glucose (mmol/L) 9.25(7.20-12.30) 7.70(6.40-9.60) 7.80(6.60-9.70) 7.30(6.23-8.80) <0.001
Insulin (μU/mL)
e 9.93 (5.85-15.06) 11.06 (6.93-17.26) 12.40 (7.93-18.24) 13.19 (8.80-20.13) 0.143
HOMA-IR
e 3.91 (2.28-6.70) 3.98 (2.36-7.21) 4.40 (2.62-7.38)) 4.44 (2.63-6.55 0.028
CRP 1.92 (0.95-4.35) 1.98 (0.71-4.92) 2.33 (0.73-5.24) 3.59 (0.81-8.87) <0.001
IMT (mm) 0.82 ± 0.21 0.85 ± 0.22 0.86 ± 0.26 0.93 ± 0.29 0.016
HbA1C (%) 7.91 ± 1.94 7.10 ± 1.59 6.96 ± 1.42 6.93 ± 1.36 <0.001
Creatinine (μmol/L) 60.67 ± 13.14 65.22 ± 19.63 67.35 ± 15.50 81.09 ± 28.75 <0.001
eGFR (ml/min/1.73
2) 132.5 ± 25.5 125.2 ± 25.4 122.5 ± 26.7 108.3 ± 31.2 <0.001
ACR (mg/mmol) 2.45 (1.25-6.04) 2.80 (1.35-9.59) 3.02 (1.54-8.11) 3.52 (1.74-8.94) 0.022
Triglycerides (mmol/L)
e 1.41 (0.97-1.91) 1.56 (1.09-2.23) 1.67 (1.17-2.41) 1.84 (1.28-2.64) <0.001
Total cholerterol (mmol/L) 5.32 ± 0.07 5.37 ± 0.07 5.44 ± 0.08 5.33 ± 0.07 0.623
LDL cholesterol (mmol/L) 2.99 ± 0.90 3.04 ± 0.84 3.11 ± 0.86 3.07 ± 0.85 0.189
HDL cholesterol (mmol/L) 1.47 ± 0.40 1.37 ± 0.36 1.26 ± 0.35 1.14 ± 0.29 <0.001
SBP, systolic blood pressure; DBP, diastolic blood pressure.; IMT, intima-media thickness
aData are means SD, median (interquartile range), or number (percent); P value was calculated after adjustment for age, gender.
bNot adjusted for itself.
cSelf-reported CVD including stroke and coronary heart disease.
dParents or siblings had a history of diabetes.
eThese variables were log transformed before analysis.
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response and could potentially modulate chronic inflam-
matory processes[25]. It is well-known that subclinical
inflammation is a risk factor not only for MetS but also
for diabetes complications such as CVD and stroke
[26,27]. Taken together, these important and intriguing
results suggest that uric acid may play a causal role in
the pathogenesis of atherosclerosis and the MetS par-
tially by inflammatory pathway.
Given the serum uric acid levels were significantly
associated with atherosclerosis and the MetS[28,29], it is
plausible to consider uric acid as a promising candidate
for risk assessment and a potential intervention target
for CVD and MetS. Interestingly, in line with our
hypothesis, some studies have demonstrated that redu-
cing uric acid by treatment with allopurinol significantly
improved endothelial function, peripheral vasodilator
capacity and blood flow both locally and systemically,
which represent a new potential therapeutic approach
[30-32]. Certainly, prospective studies with solid clinical
end points are urgently needed to clarify whether a high
uric acid level plays a causal role in the development of
CVD and MetS.
One of the interesting findings of the present study
is the inverse association of serum uric acid with dia-
betic parameters (duration of diabetes, HbA1C,F P G ) .
The inverse association of serum uric acid with dia-
betic parameters is counterintuitive. Historically, the
elevated level of uric acid observed in the MetS has
been attributed to hyperinsulinemia, since hyperinsuli-
nemia is known to be associated with impaired renal
uric acid excretion and hyperuricemia in these patients
are likely to be due to retention of uric acid[33]. But
here in our current study, the type 2 diabetes patients
with a higher HbA1C,f a s t i n gg l u c o s ea n dal o n g e r
duration of diabetes are likely to be accompanied by
worsening function of beta cells to secrete adequate
amounts of insulin. And the inverse relationship
between serum uric acid and diabetic parameters
(duration of diabetes, HbA1C,F P G )o b s e r v e di nt h e s e
diabetic subjects may probably be caused by the
increased renal excretion of uric acid in the presence
of hyperglycaemia. It is well-known that with the
increasing of the duration of diabetes, which is accom-
panied by worsening of the function of beta cells and
deterioration of glycemic control, the rate of renal fil-
tration in patients with diabetes increases gradually.
The hyperfiltration state which caused by hyperglycae-
mia promotes the excretion of uric acid, which partly
explain the existence of the inverse relationship
between serum uric acid and diabetic parameters.
Patients with long-term hyperfiltration state may even-
tually develop into diabetic nephropathy. Consistent
with our hypothesis, we observed that ACR increased
and eGFR decreased with serum uric acid quartiles
in this study (p values were 0.022 and 3.7 × 10
-5,
respectively).
As a cross-sectional study, there are several limita-
tions. The mechanisms underlying these associations are
Table 2 Correlation between serum uric acid and other
parameters in patients with type 2 diabetes
a
Variable Correlation coefficient P value
Age 0.04 0.19
BMI 0.15 <0.001
Duration of diabetes -0.14 <0.001
Waist circumference 0.21 <0.001
Waist to hip ratio 0.08 0.01
SBP 0.04 0.23
DBP 0.02 0.48
CRP 0.08 0.01
Glucose -0.26 <0.001
Insulin 0.11 <0.001
HbA1C -0.24 <0.001
HOMA-IR 0.07 0.02
IMT 0.07 0.02
Creatinine 0.33 <0.001
eGFR -0.36 <0.001
ACR 0.11 <0.001
Triglycerides -0.04 0.20
Total cholesterol 0.20 <0.001
LDL cholesterol 0.01 0.80
HDL cholesterol -0.33 <0.001
IMT, intima-media thickness; SBP, systolic blood pressure; DBP, diastolic blood
pressure;
aAll correlation coefficients were calculated after adjustment for age, gender.
Figure 1 Plasma uric acid levels according to the number of
MetS components. Data are shown as means ± SE after
adjustment for age, gender, eGFR, alcohol drinking, smoking,
duration of diabetes, self-reported CVD, and family history of
diabetes; P < 0.001 for trend.
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limited in the ability to eliminate causal relationships
between uric acid and MetS. Although most potential
confounders were carefully controlled, since some of the
study patients had several risk factors including hyper-
tension and dyslipidemia, we could not eliminate the
possible effect of underlying diseases and medications
used for these diseases on the present findings. Further
prospective population-based trials are needed to inves-
tigate the mechanisms in order to answer these
questions.
In conclusion, our data indicate that serum uric acid
levels are significantly associated with MetS and carotid
atherosclerosis in patients with type 2 diabetes, even
after adjustment for other potential confounders.
Furthermore, our findings suggest that the observed
association between uric acid and carotid atherosclero-
sis may be attributed to metabolic syndrome-depen-
dent and -independent mechanisms. Prospective
studies are required to assess the time course and cau-
sal relevance of serum uric acid in the development of
MetS and carotid atherosclerosis in patients with type
2d i a b e t e s .
Conflict of interests statement
The authors declare that they have no competing interests.
Acknowledgements
This work was supported by the National Natural Science Foundation of
China (81000344, 81070238, 81030014), Shanghai Education Committee
Foundation (11ZZ33), Shanghai Pujiang Foundation(PJ1408400), Shanghai
Science and Technology Commission (08JC1403200, 09DZ1950200), the
National High Technology Research and Development Program ("863”
Program) of China (2009AA022704), China Postdoctoral Science Foundation
(20080440078), and Shanghai Postdoctoral Scientific Program (09R21411600).
Author details
1Institute of endocrinology and diabetology, Huashan hospital, Shanghai
medical college, Fudan University. 12 Middle Wulumuqi Road, Shanghai,
China.
2Department of endocrinology, Shanghai tenth people’s hospital,
School of medicine, Tongji University. 301 Middle Yanchang Road, Shanghai,
China.
Authors’ contributions
ZY and RH designed the study; QL, ZY, LC, XT and WZ participated in
acquisition of data; JW, ZZ, BL and SQ researched and evaluated the
literature; ZY undertook the statistical analysis and QL wrote the first draft of
the manuscript. All authors have approved the final manuscript for
publication.
Received: 23 July 2011 Accepted: 4 August 2011
Published: 4 August 2011
References
1. Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, Masuda T,
Izumi T: Elevated circulating levels of an incretin hormone, glucagon-like
peptide-1, are associated with metabolic components in high-risk
patients with cardiovascular disease. Cardiovascular Diabetology 2010,
9(17).
2. Gu DF, Reynolds K, Wu XG, Chen F, Duan XF, Reynolds RF, Whelton PK,
He J, Inter ACG: Prevalence of the metabolic syndrome and overweight
among adults in China. Lancet 2005, 365(9468):1398-1405.
3. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD: Serum Uric
Acid and Risk of Coronary Heart Disease: Atherosclerosis Risk in
Communities (ARIC) Study. Annals of Epidemiology 2000, 10(3):136-143.
4. So A, Thorens B: Uric acid transport and disease. Journal of Clinical
Investigation 2010, 120(6):1791-1799.
5. Koenig W, Meisinger C: Uric acid, type 2 diabetes, and cardiovascular
diseases: Fueling the common soil hypothesis? Clinical Chemistry 2008,
54(2):231-233.
6. Meisinger C, Koenig W, Baumert J, Doring A: Uric acid levels are
associated with all-cause and cardiovascular disease mortality
independent of systemic inflammation in men from the general
population - The MONICA/KORA cohort study. Arteriosclerosis Thrombosis
and Vascular Biology 2008, 28(6):1186-1192.
Table 3 Adjusted ORs and 95% CIs for MetS and carotid plaque according to uric acid quartiles
ORs (95% CI) P value for trend
Q1 Q2 Q3 Q4
MetS
Model 1
a 1.0 1.42 (0.99-2.04) 2.27 (1.51-3.42) 3.97 (2.58-6.13) <0.001
Model 2
b 1.0 1.37 (0.95-1.98) 2.21 (1.44-3.39) 3.65 (2.33-5.71) <0.001
Model 3
c 1.0 1.33 (0.88-2.07) 2.27 (1.36-3.71) 3.77 (2.26-6.29) <0.001
Model 4
d 1.0 1.22 (0.82-1.83) 1.93 (1.22-3.03) 3.26 (2.03-5.25) <0.001
carotid plaque
Model 1* 1.0 1.33 (0.88-1.89) 1.89 (1.16-2.85) 2.71 (1.62-4.47) 0.013
Model 2
† 1.0 1.29 (0.82-1.81) 1.82 (1.13-2.77) 2.53 (1.49-4.13) 0.019
Model 3
‡ 1.0 1.22 (0.81-1.85) 1.68 (1.12-2.58) 2.42 (1.40-3.75) 0.020
Model 4
ξ 1.0 1.18 (0.80-1.76) 1.52 (1.04-2.50) 2.21 (1.32-3.49) 0.036
aModel 1 adjusted for age and gender.
bModel 2 further adjusted for alcohol drinking, smoking, duration of diabetes, and family history of diabetes.
cModel 3 further adjusted for eGFR, CRP, HbA1C and HOMA-IR.
dModel 4 further adjusted for BMI.
*Model 1 adjusted for age and gender.
†Model 2 further adjusted for alcohol drinking, smoking, duration of diabetes, and family history of diabetes.
‡Model 3 further adjusted for eGFR, CRP, HbA1C and HOMA-IR.
ξModel 4 further adjusted for BMI and MetS.
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